Champions Oncology, Inc. (CSBR) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Champions Oncology, Inc. (CSBR:NASDAQ), powered by AI.

Current Price
$6.50
P/E Ratio
18.9
Market Cap
89M
Sector
Healthcare
What is the Champions Oncology, Inc. stock price forecast?

Champions Oncology, Inc. is currently trading at $6.50. View real-time AI analysis on Alpha Lenz.

What is Champions Oncology, Inc. insider trading activity?

View the latest insider trading data for Champions Oncology, Inc. on Alpha Lenz.

What is Champions Oncology, Inc.'s P/E ratio?

Champions Oncology, Inc.'s P/E ratio is 18.9.

Champions Oncology, Inc.

NASDAQ · CSBR
$6.50+0.08(+1.25%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Champions Oncology, Inc.'s future dividend policy...
Alpha Chat Insight

Champions Oncology, Inc. trades at a P/E of 18.9 (fair value) with strong ROE of 503.0%.

Ask for details

Company Overview

Champions Oncology, Inc. operates as a biotechnology company with a core focus on developing advanced technologies and research models to enhance drug discovery and therapeutic applications in oncology. The primary function of Champions Oncology is to provide personalized solutions that support pharmaceutical companies and research institutions in understanding the complex biology of cancer. This is achieved through their pioneering ex vivo and in vivo platforms, primarily the TumorGraft Technology, which enables the testing of cancer therapies on live patient-derived tumor cells in a controlled environment. Champions Oncology plays a critical role in the pharmaceutical industry by offering predictive insights that can accelerate the development pipeline and potential success of oncology drugs. This service is crucial for researchers targeting various cancer types as they seek to understand treatment responses and develop targeted therapies. The company's offerings have significant implications in advancing precision medicine and optimizing clinical trial design, making it a valued partner for innovative cancer research initiatives globally.

CEOMr. Robert Brainin
SectorHealthcare
IndustryBiotechnology
Employees213

Company Statistics

FY 2025

Profile

$88.79MMarket Cap
$56.94MRevenue
0.00Shares Out
213Employees

Margins

50.15%Gross
11.90%EBITDA
8.51%Operating
8.12%Pre-Tax
8.26%Net

Valuation

18.89P/E
23.54P/B
1.56EV/Sales
12.55EV/EBITDA
12.69P/FCF

Growth (CAGR)

5.06%Rev 3Yr
12.13%Rev 5Yr
99.86%Op Inc 3Yr
N/AOp Inc 5Yr
104.71%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

16.08%ROA
503.05%ROE
16.57%ROIC

Financial Health

$9.79MCash & Cash Equivalents
$18.79MNet Debt
757.48%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Champions Oncology, Inc. (ticker: CSBR) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 213 employees. Market cap is $89M.

The current price is $6.5 with a P/E ratio of 18.89x and P/B of 23.54x.

ROE is 503.05% and operating margin is 8.51%. Annual revenue is $57M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Champions Oncology, Inc. (CSBR) Stock Forecast 2026 $6.50 — Price, Financials & Analyst Targets | Alpha Lenz